pleased following results. release positive welcome, fiscal second of company the operations for $XXX inflection in 'XX. incurred you speaking financial achievement our loss in history. and million with be consolidated from a Roger, of to business quite you, an quarter a quarter clearly everyone. in than our This 'XX I'm point culminated first and fiscal income is that Which operating significant extremely Thank more today
our adjusted up last quarter sixth the is with Also another last million, at compared now our million the positive remained Rx September segment. accomplishment $XX.X $X.X the balance all during a million was quarter. cash million, end the of steady at to very adjusted Equally of quarters EBITDA $X.X EBITDA X important, quarter, out key $XX to all strong positive year. for Further, our this from of
to remind are Pharma in the in on our reposition and The which development indefinitely continue a you Aytu our I'll Consumer specialty clinical 'XX, wind down announced focused profitable strategic 'XX. when mid-calendar operating this clearly company working. repositioning that undertaken we suspended therapeutics we with segment, Health programs prescription and novel initiatives we've of started growing as of commercializing October
X These on been nicely business parts the been and masked Rx our perspective. and strength cash drain were of which our profitable has growing a a of segment from has segment,
X carbonate QX treat allergic on X rapidly around to multivitamins, for of indicated quarterly to years growing extended-release June, which focused Tri-Vi-Flor, Health segment posted complementary year. up suspension older. portfolio ER, end Aytu business our And antihistamine be highlighted the prescription well XX%, wound almost and Pediatric and based last $XX.X Poly-Vi-Flor which will go-forward the as ADHD the completed record of fluoride-based Consumer carbinoxamine be should With as conditions million, our of compared patients revenues by down, completely portfolio, just an
up the Rx revenue of million, by up our QX our future segment whole, prescription from $XX financial anticipated, margin $X.X we believe growth EBITDA continued of segment XX% coupled the Aytu last gross improvement, Rx $XX.X With operational million of with net up further of reported income year, $X.X profile million. million, looks driven strong. Rx million from from improvements, and $X.X XX%, year. profit margin segment On of last adjusted ongoing
on expand the Pediatric detail, both let starting run with portfolios, in within more ADHD To ADHD. key me financials our and through few points a
our net quarter revenue, in experienced mentioned, portfolio the a Aytu XX% ADHD an of year-over-year I to million. As increase second $XX.X record during
by we best-in-class. prescriptions and due impressive a to second leverage grew believe improvements, ADHD is our force improved our revenue along an coverage portfolio gross the which Scripps with of XX.X% Aytu last was execution, The net prescribers in in of growth increase to significant to net ADHD program over year. quarter in platform, sales continuing RxConnect innovative brands, driven strong
On piece some authored expose in prescription an may it to drug address the help U.S. opaque medical discussing economics, recently that of system the transparency you of have op-ed seen surrounds pricing drugs. topic prescription RxConnect, that are pricing
pharmacies. Our lower deliver X,XXX-plus regular pricing if drug plan directly through products to out-of-pocket partner costs than transparent RxConnect prescriptions nationwide retail at works our our were to through pharmacies, way flow our
with bold and costs like commitment to patients Support Patient platform, RxConnect access who along is innovative leading options RxConnect. through It the programs ensure to our for our companies change. with of real like predictability patients is need out-of-pocket action ours, charge through we It taking like are real provide our products
for products. remains our team committed ensuring clear Our to novel predictable costs out-of-pocket
we've stimulant execution, in including generic within Adderall several for to evolving about discontinued In together the the and past and operational as methylphenidate to the products quarters late. various persist, talked disruptions of being the supply addition all products, continue ADHD our IR market strong few trends ER
news impact discontinued week. the their generic aired reporting XR Adderall XR shortages generic as recently now This and are X of to as Currently, Articles is have altogether. manufacturers as and Broadcast generics manufacturers drug week issues, Adderall last across are X the test this country. negatively highlighting continue of reports patients which
of methylphenidate extended have were to their January, relates discontinued of end shortages X while it As methylphenidate, ER methylphenidate manufacturers reporting the release of as X products.
both equation and as side with adults continue we see ADHD in forecasting, FDA year. prescription the the the been this growth an has of yet diagnoses stressed constrained, the also supply on increase While system is to more children of demand new
the As supply Cotempla. we've have demand of challenges job having these to and exceptional demands growing patients, meeting meet an Adzenys for the market-wide maintained supply continued, done
a amphetamine ADHD the for Adzenys, approved bioequivalent XR. of as ODT the to treatment Adderall is and As reminder, extended-release only approved
to is ongoing continue capture brand extended-release means well share, our remains remains So market supply additional positioned and unpredictable. shortage to as rather the very amphetamine
methylphenidates. continue and and competes are the of prescribers Cotempla of more is for in for ongoing and the being with several other eye it ADHD which Cotempla. experience to with continuing more patients opportunity is methylphenidate discontinued. future one both a Again, that the treatment We some only approved situation get Concerta fashion. supply And foreseeable the and extended-release ODT likely for against extended-release and to will ADHD, form that, Adzenys or view
teams becoming factors: is that to manufacturing one, team's the two, our ability our share leveraging increased effectively due simultaneously CMO; increasingly and on strong success brand, while Aytu is benefits to demand, also increased our market X the execution to new It we transition commercial while RxConnect. working key our apparent meeting achieved have to focus and of capture to showcase
that Pediatric proud to more primarily have to time turmoil team tremendous as a we what total as couldn't net segment in revenues. I patients scripps XX% discussed about the of changes. our revenues Transitioning our our Similar of quarter of this were needs of ordering customer a of Rx second meet portfolio quarter, timing, represents result by last to be reminder, in during seeking execution Pediatrics, ADHD. market impacted solutions now been payer of so desperately which the
excited multiple We've for it being initiatives expanding commercial January, the seen made good month during significantly implemented the looking some to and sign. December resulted distribution our units shipped Poly-Vi-Flor quarter, of recently channel, in when also have great progress base, it. very see a having unstacking This of which is of 'XX. up at versus has the customer We're
There's But the to be the based And the direction. quarter. Pediatric on EBITDA fact, we're done. for of heading for what despite we now the a trend in see Pediatric revenue Rx is, positive quarter, the healthy seeing, believe adjusted still pleased we're very the to in very million soft portfolio $X.X segment in work
our to pharmaceutical both included of been only Aytu but flows. grow turn multipronged which not also So development over negative a before transition operation, can to away our programs, it's which it segment from Rx I wrap cash pipeline things our up focused and to objective profitability. and highly Consumer Mark, generated a achieve company segment Health To that
quarters positive business X trailing is for Rx While last X the last to X adjusted accomplishment. of by million, we a transition the income our quarters, have ability of tremendous $XX -- EBITDA to of witnessed X-quarter the adjusted company-wide segment this operating EBITDA been
Mark? then and before Mark, me it things the turning call back to over to over now to Let come questions. wrap up turn I'll
